Barinthus Biotherapeutics Files 8-K

Ticker: BRNS · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1828185

Barinthus Biotherapeutics PLC. 8-K Filing Summary
FieldDetail
CompanyBarinthus Biotherapeutics PLC. (BRNS)
Form Type8-K
Filed DateJan 10, 2025
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$112 million, $2.5 million
Sentimentneutral

Sentiment: neutral

Topics: operations, executive-changes, financial-reporting

TL;DR

Barinthus Biotherapeutics dropped an 8-K detailing operations, exit costs, and exec changes. Check it out.

AI Summary

Barinthus Biotherapeutics plc. filed an 8-K on January 10, 2025, reporting on results of operations, costs associated with exit or disposal activities, and changes in directors and officers. The filing also includes information on compensatory arrangements for certain officers and Regulation FD disclosures. Exhibits and financial statements are also part of the report.

Why It Matters

This 8-K filing provides crucial updates on Barinthus Biotherapeutics' operational results, potential restructuring costs, and executive team changes, which can significantly impact investor understanding of the company's current standing and future direction.

Risk Assessment

Risk Level: medium — The filing covers a range of topics including operational results, potential exit costs, and executive changes, which could indicate significant company events or strategic shifts.

Key Players & Entities

  • Barinthus Biotherapeutics plc. (company) — Filer of the 8-K report
  • January 10, 2025 (date) — Date of the earliest event reported
  • Vaccitech plc (company) — Former company name
  • Vaccitech Ltd (company) — Former company name

FAQ

What specific results of operations are detailed in this 8-K filing?

The filing indicates that results of operations are a key item reported, but the specific details are not provided in the provided text.

Are there any significant costs associated with exit or disposal activities mentioned?

Yes, the filing explicitly lists 'Cost Associated with Exit or Disposal Activities' as an item information, suggesting such costs are being reported.

What changes are reported regarding the company's directors or officers?

The filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' indicating changes in the company's leadership.

Does the filing include information on compensatory arrangements for officers?

Yes, the filing mentions 'Compensatory Arrangements of Certain Officers' as a reported item.

What is the former name of Barinthus Biotherapeutics plc?

Barinthus Biotherapeutics plc. was formerly known as Vaccitech plc, and prior to that, Vaccitech Ltd.

Filing Stats: 1,443 words · 6 min read · ~5 pages · Grade level 13.4 · Accepted 2025-01-10 08:02:06

Key Financial Figures

  • $112 million — and restricted cash are expected to be $112 million as of December 31, 2024. The prelimin
  • $2.5 million — e-related costs may be in the region of $2.5 million with the majority of such costs being i

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On January 10, 2025, Barinthus Biotherapeutics plc (the "Company") released the following preliminary information about its cash, cash equivalents and restricted cash as of December 31, 2024. The Company's preliminary estimated cash, cash equivalents and restricted cash are expected to be $112 million as of December 31, 2024. The preliminary estimates of cash and cash equivalents reflect management's current views and may change as a result of management's review of results and other factors. The preliminary estimates may not ultimately be indicative of its results for such period and actual results may differ materially. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary estimated results, nor have they expressed any opinion or any other form of assurance on these preliminary estimated results.

05. Costs Associated with Exit or Disposal Activities

Item 2.05. Costs Associated with Exit or Disposal Activities. On January 10, 2025, the Company announced a restructuring plan that aims to prioritize its immune tolerance research and development programs. The Company is planning a 65% reduction in workforce, which is subject to consultation with employee representatives in the UK regarding the plan. The Company anticipates that the majority of the reduction in workforce will occur in the UK and be completed during the first half of 2025. The Company estimates that the pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $2.5 million with the majority of such costs being incurred in the first half of 2025. The estimates of the restructuring costs that the Company expects to incur and potential operating expense reductions, and the timing thereof, are subject to a number of assumptions and actual results may differ. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the restructuring, the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025 and the employment of Gemma Brown effective as of April 30, 2025. Further plans for the re-organized team will be communicated in due course. In connection with these changes, the Company intends to enter into severance agreements with Mr. Griffiths and Ms. Brown, reflecting substantially the terms set forth in their respective service agreements.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 10, 2025, the Company issued a press release titled "Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On January 10, 2025, the Company updated its corporate presentation for use in meetings with investors, analysts and others. A copy of this presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the presentation. The information in Items 2.02 and 7.01 of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words "expect," "will," and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding the Company's preliminary estimated cash and cash equivalents and future expectations, plans and prospects, including the Company's product development activities and clinical trials and the estimates of costs that the Company expects to incur in connection with the restructuring and the timing thereof. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, risks and uncertainties related to the success, cost and timing of the Company's pipeline development activities and planned and ongoing clinical trials, the Company's ability to execute on its strategy, regulatory developments, the risk that the Company may not achieve the anticipated benefits of its pipeline prioritization and corporate restructuring, the Company's ability to fund its operations and access capital, the Company's preliminary estimates of its cash and cash equivalents, including the risk that final financial results may differ materially from the Company's preliminary estimates, and other risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated January 10 , 2025. 99.2 Corporate Deck dated January 1 0 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Barinthus Biotherapeutics plc Date: January 10, 2025 By: /s/ William Enright William Enright Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.